Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
You may also be interested in...
Roche’s pRED Team Reviews R&D Wish List As Firm Continues Push To Diversify
In an interview at the J.P. Morgan meeting, Roche R&D and partnering execs John Reed and Sophie Kornowski-Bonnet review progress and aspirations in new therapeutic areas like ophthalmology, antimicrobials and CNS diseases.
Bitopertin’s Schizophrenia Failure Stirs Doubt About Roche’s CNS Plans
Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.